1207454-56-5

Basic information

• Product Name: LT-673
• Synonyms: 3H-Pyrido[4,3,2-de]phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-Methyl-1H-1,2,4-triazol-5-yl)-;5-fluoro-8-(4-fluorophenyl)-9-(1-Methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-;5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de];5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one;5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one
• CAS NO: 1207454-56-5
• Molecular Formula: C₁₉H₁₄F₂N₆O
• Molecular Weight: 380.3508664
• Mol File: 1207454-56-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.63±0.1 g/cm3(Predicted)
• PKA: 10.14±0.60(Predicted)
• CAS DataBase Reference: LT-673(CAS DataBase Reference)
• NIST Chemistry Reference: LT-673(1207454-56-5)
• EPA Substance Registry System: LT-673(1207454-56-5)

Safety Data

• Hazardous Substances Data: 1207454-56-5(Hazardous Substances Data)

Usage

Uses

BMN 673 is a pyrrolopyrazine derivative and anpoly (ADP-ribose) polymerase (PARP) inhibitor for patients with advanced or recurrent solid tumors such as ovarian and breast cancer.

Upstream product

• 1207454-57-6 ethyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 459-57-4 4-fluorobenzaldehyde 
• 1322879-81-1 methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate 
• 1322616-36-3 methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1322616-38-5 (E)-7-fluoro-5-(4-fluorobenzylideneamino)-4-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)phthalazin-1(2H)-one 
• 1322616-39-6 (E)-methyl 5-fluoro-2-(3-(4-fluorophenyl)-2-(1-methyl-1H-1,2,4-triazol-5-yl)acryloyl)-3-nitrobenzoate 
• 1322616-40-9 methyl 7-fluoro-2-(4-fluorophenyl)-1-hydroxy-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-90-4 6-fluoro-4-nitroisobenzofuran-1(3H)-one 
• 1322616-34-1 (Z)-6-fluoro-3-((1-methyl-1H-1,2,4-triazol-5-yl)methylene)-4-nitroisobenzofuran-1(3H)-one 
• 1322616-37-4 5-amino-7-fluoro-4-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)phthalazin-1(2H)-one 

Downstream Products

• 1207456-01-6 ((11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5⁽¹³⁾,6,8-tetraen-4-one) 
• 1207456-00-5 (8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3 ,2-de] phthalazin-3(7H)-one 

Relevant articles and documents

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA

Provided is a methods of treating multiple myeloma with inhibitors of poly(ADP-ribose)polymerase according to Formula (I):

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1 , R2 , R3 , R4 and R5 are as defined herein. Provided herein are inhibitors of poly (ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity